Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis

Clinical and Vaccine Immunology

Volumn 16, Issue 3, 2009, Pages 430-432

  Saville, Stephen P ^a   Lazzell, Anna L ^a   Chaturvedi, Ashok K ^a   Monteagudo, Carlos ^b   Lopez Ribot, Jose L ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANDIDA ALBICANS VACCINE; LIVE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FUNGAL STRAIN; GENETIC ENGINEERING; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; INVASIVE CANDIDIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ANIMALS; CANDIDA ALBICANS; CANDIDIASIS; FUNGAL VACCINES; MICE; NEUREGULIN-1; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 61949135572     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00480-08     Document Type: Article

References (22)

1. Ashman, R. B., E. M. Bolitho, and J. M. Papadimitriou. 1993. Patterns of resistance to Candida albicans in inbred mouse strains. Immunol. Cell Biol. 71:221-225.
2. Ashman, R. B., J. M. Papadimitriou, A. Fulurija, K. E. Drysdale, C. S. Farah, O. Naidoo, and T. Gotjamanos. 2003. Role of complement C5 and T lymphocytes in pathogenesis of disseminated and mucosal candidiasis in susceptible DBA/2 mice. Microb. Pathog. 34:103-113.
3. Banerjee, S. N., T. G. Emori, D. H. Culver, R. P. Gaynes, W. R. Jarvis, T. Horan, J. R. Edwards, J. Tolson, T. Henderson, and W. J. Martone. 1991. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am. J. Med. 91:86S-89S.
4. Beck-Sague, C., and W. R. Jarvis. 1993. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J. Infect. Dis. 167:1247-1251.
5. Belshe, R. B. 2007. Translational research on vaccines: influenza as an example. Clin. Pharmacol. Ther. 82:745-749.
6. Deepe, G. S., Jr. 1997. Prospects for the development of fungal vaccines. Clin. Microbiol. Rev. 10:585-596.
7. Dixon, D. M., A. Casadevall, B. Klein, L. Mendoza, L. Travassos, and G. S. Deepe, Jr. 1998. Development of vaccines and their use in the prevention of fungal infections. Med. Mycol. 36(Suppl. 1):57-67.
8. Fonzi, W. A., and M. Y. Irwin. 1993. Isogenic strain construction and gene mapping in Candida albicans. Genetics 134:717-728.
9. Gudlaugsson, O., S. Gillespie, K. Lee, J. Vande Berg, J. Hu, S. Messer, L. Herwaldt, M. Pfaller, and D. Diekema. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37:1172-1177.
10. Ibrahim, A. S., B. J. Spellberg, V. Avenissian, Y. Fu, S. G. Filler, and J. E. Edwards, Jr. 2005. Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect. Immun. 73:999-1005.
11. Mochon, A. B., and J. E. Cutler. 2005. Is a vaccine needed against Candida albicans? Med. Mycol. 43:97-115.
12. Pirofski, L. A., and A. Casadevall. 1998. Use of licensed vaccines for active immunization of the immunocompromised host. Clin. Microbiol. Rev. 11:1-26.
13. Rentz, A. M., M. T. Halpern, and R. Bowden. 1998. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin. Infect. Dis. 27:781-788.
14. Romani, L., A. Mencacci, E. Cenci, P. Mosci, G. Vitellozzi, U. Grohmann, P. Puccetti, and F. Bistoni. 1992. Course of primary candidiasis in T cell-depleted mice infected with attenuated variant cells. J. Infect. Dis. 166:1384-1392.
15. Romani, L., A. Mencacci, E. Cenci, R. Spaccapelo, P. Mosci, P. Puccetti, and F. Bistoni. 1993. CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance. J. Immunol. 150:925-931.
16. Sanglard, D., and F. C. Odds. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2:73-85.
17. Saville, S. P., A. L. Lazzell, A. P. Bryant, A. Fretzen, A. Monreal, E. O. Solberg, C. Monteagudo, J. L. Lopez-Ribot, and G. T. Milne. 2006. Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob. Agents Chemother. 50:3312-3316.
18. Saville, S. P., A. L. Lazzell, A. K. Chaturvedi, C. Monteagudo, and J. L. Lopez-Ribot. 2008. Use of a genetically engineered strain to evaluate the pathogenic potential of yeast cell and filamentous forms during Candida albicans systemic infection in immunodeficient mice. Infect. Immun. 76:97-102.
19. Saville, S. P., A. L. Lazzell, C. Monteagudo, and J. L. Lopez-Ribot. 2003. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot. Cell 2:1053-1060.
20. Spellberg, B. J., A. S. Ibrahim, V. Avenissian, S. G. Filler, C. L. Myers, Y. Fu, and J. E. Edwards, Jr. 2005. The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect. Immun. 73:6191-6193.
21. Viudes, A., J. Peman, E. Canton, P. Ubeda, J. L. Lopez-Ribot, and M. Gobernado. 2002. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur. J. Clin. Microbiol. Infect. Dis. 21:767-774.
22. Wey, S. B., M. Mori, M. A. Pfaller, R. F. Woolson, and R. P. Wenzel. 1988. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch. Intern. Med. 148:2642-2645.